Literature DB >> 1389902

Tumor-infiltrating lymphocytes as antitumor effector cells.

T L Whiteside1.   

Abstract

Mesh：

Year:  1992        PMID： 1389902     DOI： 10.1007/bf02194785

Source DB:  PubMed          Journal:  Biotherapy        ISSN： 0921-299X


× No keyword cloud information.
  7 in total

1.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

Review 2.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

Review 3.  Relevance of the T cell receptor for immunotherapy of cancer.

Authors:  E Weidmann; M Trucco; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

4.  Oligoclonality of CD8+ T cells in breast cancer patients.

Authors:  K Ito; J Fetten; H Khalili; S Hajdu; E Busch; R Pergolizzi; V Vinciguerra; M D Chang
Journal:  Mol Med       Date:  1997-12       Impact factor: 6.354

5.  Specific tumor memory induced by polyethylene-glycol-modified interleukin-2 requires both helper and cytotoxic T cells.

Authors:  L T Balemans; P A Steerenberg; B H Kremer; F J Koppenhagen; P H De Mulder; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

6.  A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.

Authors:  P Correale; L Micheli; M T Vecchio; M Sabatino; R Petrioli; D Pozzessere; S Marsili; G Giorgi; L Lozzi; P Neri; G Francini
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

7.  Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2.

Authors:  F De Paola; R Ridolfi; A Riccobon; E Flamini; F Barzanti; A M Granato; G L Mordenti; L Medri; P Vitali; D Amadori
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.